

REMARKS

Status of the claims:

With the above amendments, claims 7, 29, 30, 35, 45, 55, 67, 79, and 81 are canceled, and claims 1, 8, and 82-106 are pending and ready for further action on the merits. No new matter has been added by way of the above amendments. Support for new claims 82-106 can be found for example in claims 2-6 and 9-28 as filed in the PCT application from which this 35 U.S.C. § 371 filing is derived. Applicants request favorable consideration in light of the following remarks.

Restriction Requirement/ Election of Species

The Examiner has set out the following restriction requirement:

Group I: claims 1 and 8 drawn to a method of identifying a compound;

Group II: claim 7 drawn to compound identified by the method of claim 1;

Group III: claim 9 drawn to compound identified by the method of claim 8;

Group IV: claim 30 drawn to method of generating a 3D model;

Group V: claim 35 drawn to a computer model;

Group VI: claim 45 drawn to a pharmacophore;

Group VII: claim 55 drawn to a compound comprising at least one atom;

Group VIII: claim 67 drawn to a pharmaceutical composition;

Group IX: claim 79 drawn to method for conducting drug discovery;

Group X: claim 81 drawn to method of treatment.

Applicants elect Group I without traverse. Applicants submit that new claims 82-106 also fit within the scope of the elected group. Thus, all pending claims should rightfully be examined together.

Election of Species

The Examiner has also required an election of species. Applicants elect as a protein species, protein I7L with traverse. The basis of the traversal is that the possible species set out by the Examiner on page five of the Restriction Requirement of August 26, 2008 are so linked that each possesses the same technical features that define a contribution which each of the claimed inventions, when considered as a whole, makes over the prior art. Accordingly, under the election of species procedure as set out at MPEP 806.01 *et seq.*, Applicants submit for the election of species there is unity of invention between the various species.

Fees

Applicants herein petition for a one month extension fee. The Commissioner is hereby authorized to charge any additional fees required by this action or any future action to Deposit Account No. 16-1435.

Should the Examiner have any questions relating to the instant application, the Examiner is invited to telephone the undersigned at (336) 607-7486 to discuss any issues.

Respectfully submitted,

Date: October 27, 2008

Ben Schroeder

T. Benjamin Schroeder (Reg. No. 50,990)

KILPATRICK STOCKTON LLP
1001 West Fourth Street
Winston-Salem, North Carolina 27101-2400
Phone: (336) 607-7486
Facsimile: (336) 607-7500